PubMed:8045270 JSONTXT

{"project":"bc5cdr-valid-experiment","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":27,"end":36},"obj":"Chemical"},{"id":"T3","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T4","span":{"begin":120,"end":129},"obj":"Chemical"},{"id":"T5","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T6","span":{"begin":243,"end":253},"obj":"Disease"},{"id":"T7","span":{"begin":320,"end":329},"obj":"Chemical"},{"id":"T8","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T9","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T10","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T11","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T12","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T13","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T14","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T15","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T16","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T17","span":{"begin":848,"end":855},"obj":"Chemical"},{"id":"T18","span":{"begin":878,"end":887},"obj":"Chemical"},{"id":"T19","span":{"begin":994,"end":1003},"obj":"Chemical"},{"id":"T20","span":{"begin":1043,"end":1050},"obj":"Chemical"},{"id":"T21","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-deepseek-nr-ng","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T3","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T4","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T5","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T6","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T7","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T8","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T9","span":{"begin":760,"end":767},"obj":"Chemical"},{"id":"T10","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T11","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-gemini-nr-ng","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":27,"end":60},"obj":"Chemical"},{"id":"T3","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T4","span":{"begin":120,"end":153},"obj":"Chemical"},{"id":"T5","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T6","span":{"begin":243,"end":253},"obj":"Disease"},{"id":"T7","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T8","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T9","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T10","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T11","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T12","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T13","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T14","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T15","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T16","span":{"begin":848,"end":855},"obj":"Chemical"},{"id":"T17","span":{"begin":878,"end":911},"obj":"Chemical"},{"id":"T18","span":{"begin":994,"end":1028},"obj":"Chemical"},{"id":"T19","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":27,"end":36},"obj":"Chemical"},{"id":"T3","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T4","span":{"begin":120,"end":129},"obj":"Chemical"},{"id":"T5","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T6","span":{"begin":243,"end":253},"obj":"Disease"},{"id":"T7","span":{"begin":320,"end":329},"obj":"Chemical"},{"id":"T8","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T9","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T10","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T11","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T12","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T13","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T14","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T15","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T16","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T17","span":{"begin":848,"end":855},"obj":"Chemical"},{"id":"T18","span":{"begin":878,"end":887},"obj":"Chemical"},{"id":"T19","span":{"begin":994,"end":1003},"obj":"Chemical"},{"id":"T20","span":{"begin":1043,"end":1050},"obj":"Chemical"},{"id":"T21","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-gemini-r-g","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":27,"end":36},"obj":"Chemical"},{"id":"T3","span":{"begin":66,"end":80},"obj":"Disease"},{"id":"T4","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T5","span":{"begin":120,"end":129},"obj":"Chemical"},{"id":"T6","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T7","span":{"begin":243,"end":253},"obj":"Disease"},{"id":"T8","span":{"begin":320,"end":329},"obj":"Chemical"},{"id":"T9","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T10","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T11","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T12","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T13","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T14","span":{"begin":519,"end":533},"obj":"Disease"},{"id":"T15","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T16","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T17","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T18","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T19","span":{"begin":878,"end":887},"obj":"Chemical"},{"id":"T20","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-gemini-r-ng","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":27,"end":60},"obj":"Chemical"},{"id":"T3","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T4","span":{"begin":120,"end":153},"obj":"Chemical"},{"id":"T5","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T6","span":{"begin":320,"end":350},"obj":"Chemical"},{"id":"T7","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T8","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T9","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T10","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T11","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T12","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T13","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T14","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T15","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T16","span":{"begin":878,"end":911},"obj":"Chemical"},{"id":"T17","span":{"begin":994,"end":1028},"obj":"Chemical"},{"id":"T18","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-gemini-nr-g","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":27,"end":36},"obj":"Chemical"},{"id":"T3","span":{"begin":70,"end":80},"obj":"Disease"},{"id":"T4","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T5","span":{"begin":120,"end":129},"obj":"Chemical"},{"id":"T6","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T7","span":{"begin":243,"end":253},"obj":"Disease"},{"id":"T8","span":{"begin":320,"end":329},"obj":"Chemical"},{"id":"T9","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T10","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T11","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T12","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T13","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T14","span":{"begin":519,"end":533},"obj":"Disease"},{"id":"T15","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T16","span":{"begin":681,"end":695},"obj":"Disease"},{"id":"T17","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T18","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T19","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T20","span":{"begin":848,"end":855},"obj":"Chemical"},{"id":"T21","span":{"begin":878,"end":887},"obj":"Chemical"},{"id":"T22","span":{"begin":1043,"end":1050},"obj":"Chemical"},{"id":"T23","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-gpt-r-g","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T3","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T4","span":{"begin":243,"end":253},"obj":"Disease"},{"id":"T5","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T6","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T7","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T8","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T9","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T10","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T11","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T12","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T13","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T14","span":{"begin":848,"end":855},"obj":"Chemical"},{"id":"T15","span":{"begin":1043,"end":1050},"obj":"Chemical"},{"id":"T16","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-gpt-r-ng","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T3","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T4","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T5","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T6","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T7","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T8","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T9","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T10","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T11","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T12","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T13","span":{"begin":848,"end":855},"obj":"Chemical"},{"id":"T14","span":{"begin":1043,"end":1050},"obj":"Chemical"},{"id":"T15","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-gpt-nr-g","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T3","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T4","span":{"begin":243,"end":253},"obj":"Disease"},{"id":"T5","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T6","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T7","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T8","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T9","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T10","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T11","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T12","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T13","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T14","span":{"begin":848,"end":855},"obj":"Chemical"},{"id":"T15","span":{"begin":1043,"end":1050},"obj":"Chemical"},{"id":"T16","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-gpt-nr-ng","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T3","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T4","span":{"begin":243,"end":263},"obj":"Disease"},{"id":"T5","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T6","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T7","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T8","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T9","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T10","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T11","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T12","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T13","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T14","span":{"begin":848,"end":855},"obj":"Chemical"},{"id":"T15","span":{"begin":1043,"end":1050},"obj":"Chemical"},{"id":"T16","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-deepseek-r-ng","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T3","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T4","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T5","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T6","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T7","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T8","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T9","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T10","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-gemini-r-m","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":27,"end":36},"obj":"Chemical"},{"id":"T3","span":{"begin":66,"end":80},"obj":"Disease"},{"id":"T4","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T5","span":{"begin":120,"end":129},"obj":"Chemical"},{"id":"T6","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T7","span":{"begin":243,"end":253},"obj":"Disease"},{"id":"T8","span":{"begin":320,"end":329},"obj":"Chemical"},{"id":"T9","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T10","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T11","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T12","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T13","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T14","span":{"begin":519,"end":533},"obj":"Disease"},{"id":"T15","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T16","span":{"begin":681,"end":695},"obj":"Disease"},{"id":"T17","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T18","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T19","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T20","span":{"begin":848,"end":855},"obj":"Chemical"},{"id":"T21","span":{"begin":878,"end":887},"obj":"Chemical"},{"id":"T22","span":{"begin":994,"end":1003},"obj":"Chemical"},{"id":"T23","span":{"begin":1043,"end":1050},"obj":"Chemical"},{"id":"T24","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-gpt-r-m2","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T3","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T4","span":{"begin":243,"end":253},"obj":"Disease"},{"id":"T5","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T6","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T7","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T8","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T9","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T10","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T11","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T12","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T13","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T14","span":{"begin":848,"end":855},"obj":"Chemical"},{"id":"T15","span":{"begin":1043,"end":1050},"obj":"Chemical"},{"id":"T16","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-deepseek-r-g","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":70,"end":80},"obj":"Disease"},{"id":"T3","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T4","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T5","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T6","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T7","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T8","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T9","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T10","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T11","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T12","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T13","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-deepseek-nr-g","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T3","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T4","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T5","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T6","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T7","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T8","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T9","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T10","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-deepseek-r-m","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T3","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T4","span":{"begin":243,"end":253},"obj":"Disease"},{"id":"T5","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T6","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T7","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T8","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T9","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T10","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T11","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T12","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T13","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T14","span":{"begin":848,"end":855},"obj":"Chemical"},{"id":"T15","span":{"begin":1043,"end":1050},"obj":"Chemical"},{"id":"T16","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}

{"project":"bc5cdr-valid-gpt-r-m","denotations":[{"id":"T1","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"T2","span":{"begin":91,"end":98},"obj":"Chemical"},{"id":"T3","span":{"begin":178,"end":185},"obj":"Chemical"},{"id":"T4","span":{"begin":243,"end":253},"obj":"Disease"},{"id":"T5","span":{"begin":352,"end":361},"obj":"Chemical"},{"id":"T6","span":{"begin":407,"end":414},"obj":"Chemical"},{"id":"T7","span":{"begin":432,"end":441},"obj":"Disease"},{"id":"T8","span":{"begin":453,"end":464},"obj":"Chemical"},{"id":"T9","span":{"begin":487,"end":496},"obj":"Chemical"},{"id":"T10","span":{"begin":638,"end":645},"obj":"Chemical"},{"id":"T11","span":{"begin":730,"end":758},"obj":"Chemical"},{"id":"T12","span":{"begin":760,"end":766},"obj":"Chemical"},{"id":"T13","span":{"begin":788,"end":799},"obj":"Chemical"},{"id":"T14","span":{"begin":848,"end":855},"obj":"Chemical"},{"id":"T15","span":{"begin":1043,"end":1050},"obj":"Chemical"},{"id":"T16","span":{"begin":1092,"end":1104},"obj":"Disease"}],"text":"KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.\nKF17837 is a novel selective adenosine A2A receptor antagonist. Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism."}